Skip to main content
SpringerLink
Log in

Adverse Effects of Intravenous Immunoglobulin

  • Review Article
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

The range of diseases in which intravenous immunoglobulin (IVIG) is effective has expanded significantly since its initial use in primary antibody deficiency. There are at present at least 17 preparations of IVIG in use worldwide with similar profiles of adverse effects. Infusion-related effects range in severity. Mild adverse reactions (headache, flushing, low backache, nausea, wheezing) are often associated with a fast infusion rate, and respond rapidly on slowing the infusion. Very rare episodes of life-threatening anaphylaxis may occur, particularly in those IgA-deficient patients with anti-IgA antibodies; such patients should receive an IgA-depleted preparation of IVIG.

There are concerns with any blood product about safety in regard to viral transmission. The 4 outbreaks of non-A non-B hepatitis (probably hepatitis C) in the 1980s were associated with the use of particular batches of IVIG. The more recent exclusion of all anti-hepatitis C virus positive individuals from the donor pool, and the introduction of specific antiviral steps in the manufacture of IVIGs, should prevent further outbreaks. The human immunodeficiency virus (HIV) is effectively inactivated during the manufacturing process itself and HIV transmission has not been reported with IVIG.

Rarely, haematological (Coombs’ test positive haemolysis), neurological (aseptic meningitis) or renal (transient rises in serum creatinine) adverse effects may be seen when high doses of IVIG are used for immunomodulatory purposes. Haemolysis, due to passive transmission of blood group antibodies (anti-A, anti-D), may be prevented by selecting IVIG batches that give a negative cross-match between the recipient’ s red cells and IVIG. The use of IVIG in the presence of rapidly progressive glomerulonephritis should be avoided.

Overall, when viewed in the context of the extensive use of IVIG worldwide over the past 10 years, the incidence of all reported adverse effects is low. IVIG is still a relatively safe product the judicious use of which is likely to prove significantly beneficial in many patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ammann AJ, Ashman RF, Buckley RH, Hardie WR, Krantmann HJ. Use of intravenous gammaglobulin in antibody immunodeficiency: results of a multicenter controlled trial. Clinical Immunology and Immunopathology 22: 60–67, 1982

    Article  PubMed  CAS  Google Scholar 

  • Ayliffe W, Haeney M, Roberts SC, Lavin M. Uveitis after antineutrophil cytoplasmic antibody contamination of immunoglobulin replacement therapy. Correspondence. Lancet 339: 558–559, 1992

    Article  PubMed  CAS  Google Scholar 

  • Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human gammaglobulin. Vox Sanguinis 7: 157–174, 1962

    Article  PubMed  CAS  Google Scholar 

  • Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, et al. Acute cryoglobulinemic renal failure after intravenous infusion of gammaglobulin. American Journal of Medicine 82: 624–629, 1987

    Article  PubMed  CAS  Google Scholar 

  • Barucha C, McMillan JC. Eczema after intravenous infusion of immunoglobulin. British Medical Journal 295: 1141, 1987

    Article  PubMed  CAS  Google Scholar 

  • Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high dose intravenous immunoglobulin: attenuation of acute complement dependent immune damage in a guinea pig model. Journal of Clinical Investigation 84: 1974–1981, 1989

    Article  PubMed  CAS  Google Scholar 

  • Bjorkander J, Cunningham-Rundles C, Lundin P, Olsson R, Soderstrom R. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. American Journal of Medicine 84: 107–111, 1988

    Article  PubMed  CAS  Google Scholar 

  • Bjorkander J, Hammarstrom L, Smith CIE, Buckley RH, Cunningham-Rundles C, et al. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. Journal of Clinical Immunology 7: 8–15, 1987

    Article  PubMed  CAS  Google Scholar 

  • Brox AG, Cournoyer D, Sternboch M, Spurll G. Hemolytic anaemia following intravenous gammaglobulin administration. American Journal of Medicine 82: 633–635, 1987

    Article  PubMed  CAS  Google Scholar 

  • Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. New England Journal of Medicine 314: 560–564, 1986

    Article  PubMed  CAS  Google Scholar 

  • Bussel JB. Modulation of Fc receptor clearance and antiplatelet antibodies as a consequence of intravenous immune globulin infusion in patients with immune thrombocytopenia purpura. Journal of Allergy and Clinical Immunology 84 (Suppl.): 566–578, 1989

    Article  PubMed  CAS  Google Scholar 

  • Casteels-Van Daele M, Wijndaele L, Hunninck K, Gillis P. Intravenous immune globulin and acute aseptic meningitis. Correspondence. New England Journal of Medicine 323: 614–615, 1990

    PubMed  CAS  Google Scholar 

  • Chan Lam D, Fitzsimons EJ, Douglas WS. Alopecia after immunoglobulin infusion. Correspondence. Lancet 1: 1436, 1987

    Article  PubMed  CAS  Google Scholar 

  • Chapel HM, Hargreaves RM, Lee M, Pamphilon D. Safety of immunoglobulin therapy in patients with multiple myeloma. Immunodeficiency, in press, 1993

    Google Scholar 

  • Chetrit EB, Putterman C. Transient neutropenia induced by intravenous immune globulin. Correspondence. New England Journal of Medicine 326: 270–271, 1992

    Article  Google Scholar 

  • Cohn EJ, Oncley JL, Strong LE, et al. Chemical, clinical and immunological studies of the products of human plasma fractionation. Journal of Clinical Investigation 23: 417–432, 1944

    Article  PubMed  CAS  Google Scholar 

  • Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM. Immune haemolysis, disseminated intravascular coagulation and serum sickness after large doses of immunoglobulin given intravenously for Kawasaki’ s disease. Journal of Paediatrics and Child Health 120: 926–928, 1992

    CAS  Google Scholar 

  • Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. IVIG for the prevention of infection in chronic lymphocytic leukemia. New England Journal of Medicine 319: 902–907, 1988

    Article  Google Scholar 

  • Corvetta A, Della-Bitta R, Gabrielli A, Spaeth PJ, Danieli G. Use of high dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clinical and Experimental Rheumatology 7: 295–299, 1989

    PubMed  CAS  Google Scholar 

  • Cross AS, Alving BM, Sadoff JC, Baldwin P, Terebelo H, et al. Intravenous immune globulin: a cautionary tale. Correspondence. Lancet 1: 912, 1984

    Article  PubMed  CAS  Google Scholar 

  • Donatini B, Goetz J, Hauptmann G. Uveitis and antineutrophil cytoplasmic antibody in immunoglobulin batches. Correspondence. Lancet 339: 1175–1176, 1992

    Article  PubMed  CAS  Google Scholar 

  • Ellie E, Combe C, Ferrer X. High dose intravenous immune globulin and acute renal failure. Correspondence. New England Journal of Medicine 327: 1032–1033, 1992

    PubMed  CAS  Google Scholar 

  • Finlayson JS, Tankersley DL. Anti-HCV screening and plasma fractionation: the case against. Correspondence. Lancet 335: 1274–1275, 1990

    Article  PubMed  CAS  Google Scholar 

  • Gerebenau MD. Transient neutropenia induced by intravenous immune globulin. Correspondence. New England Journal of Medicine 326: 271, 1992

    Article  Google Scholar 

  • Griffiths H, Brennan V, Lea J, Bunch C, Lee M, et al. Crossover study of immunoglobulin replacement therapy in patients with low grade B cell tumours. Blood 73: 366–368, 1989

    PubMed  CAS  Google Scholar 

  • Griffiths H, Lea J, Bunch C, Lee M, Chapel H. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clinical and Experimental Immunology 89: 374–377, 1992

    Article  PubMed  CAS  Google Scholar 

  • Habibi B, Garretta M. Screening for hepatitis C virus antibody in plasma for fractionation. Correspondence. Lancet 335: 855–856, 1990

    Article  PubMed  CAS  Google Scholar 

  • Hague RA, Eden OB, Yap PL, Mok JYQ, Rae P. Hyperviscosity in HIV infected children — a potential hazard during intravenous immunoglobulin therapy. Blut 61: 66–67, 1990

    Article  PubMed  CAS  Google Scholar 

  • Hammerstrom L, Smith CIE. Anaphylaxis after administration of gamma globulin for hypogammaglobulinemia. Correspondence. New England Journal of Medicine 315: 519, 1986

    Article  Google Scholar 

  • Hanson LA, Soderstrom R, Friman V, Hahn-Zoric M, Czerkinsky C, et al. Update on IgA and IgG subclass deficiency. In Chapel et al. (Eds) Progress in immune deficiency III. Royal Society of Medicine International Symposia and Congress Series, no. 173, pp. 1–6, Royal Society of Medicine, London, 1991

    Google Scholar 

  • Horst HA, Schmitz N, Glinike C, Loffier H, Laufs R. Seroconversion for Hepatitis C virus antibody in bone marrow recipients treated with immune globulin. Correspondence. New England Journal of Medicine 325: 132–133, 1991

    PubMed  CAS  Google Scholar 

  • Jayne DRW, Davies MJ, Fox CJV, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337: 1137–1139, 1991

    Article  PubMed  CAS  Google Scholar 

  • Kato E, Shindo S, Eto Y, Hashimoto N, Yamamoto M, et al. Administration of immune globulin associated with aseptic meningitis. Correspondence. Journal of the American Medical Association 259: 3269–3271, 1988

    Article  PubMed  CAS  Google Scholar 

  • Kobosko J, Nicol P. Renal toxicity of intravenous immunoglobulin. Clinical Nephrology 37: 216–217, 1992

    PubMed  CAS  Google Scholar 

  • Lever AML, Brown D, Webster ADB, Thomas HC. Non-A non-B hepatitis occuring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 2: 1062–1064, 1984

    Article  PubMed  CAS  Google Scholar 

  • Lichtiger B, Rogge K. Spurious serologic test results in patients receiving infusions of intravenous immune gammaglobulin. Archives of Pathology and Laboratory Medicine 115: 467–469, 1991

    PubMed  CAS  Google Scholar 

  • Lin CY, Hsu HC, Chiang H. Improvement of histological and immunological change in steroid and immunosuppressive drug resistant lupus nephritis by high dose intravenous gamma globulin. Nephron 53: 303–310, 1989

    Article  PubMed  CAS  Google Scholar 

  • Medical Research Council Working Party on Hypogammaglobulinaemia. Hypogammaglobulinaemia in the United Kingdom. Lancet 1: 163–168, 1969

    Google Scholar 

  • Mitra G, Wong MF, Mozen MM, McDougal JS, Levy JA. Elimination of infectious retroviruses during preparation of immunoglobulins. Transfusion 26: 394–397, 1986

    Article  PubMed  CAS  Google Scholar 

  • National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. New England Journal of Medicine 325: 73–80, 1991

    Article  Google Scholar 

  • Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, et al. A single intravenous infusion of gammaglobulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine 324: 1633–1639, 1991

    Article  PubMed  CAS  Google Scholar 

  • Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine 315: 341–347, 1986

    Article  PubMed  CAS  Google Scholar 

  • Nicholls MD, Cummins JC, Davies VJ, Greenwood JK. Haemolysis induced by intravenously administered immunoglobulin. Medical Journal of Australia 150: 404–406, 1989

    PubMed  CAS  Google Scholar 

  • Ochs HD, Fischer SH, Virant FS, Lee ML, Kingdom HS, et al. Non-A non-B hepatitis and intravenous immunoglobulin. Correspondence. Lancet 1: 404–405, 1985

    Article  Google Scholar 

  • O’Donnell JL, Ahern MJ, Roberts-Thomson PJ, Bradley J. Alteration in circulating neutrophil CR3 density associated with immunoglobulin infusion. Australian and New Zealand Journal of Medicine 18: 95–100, 1988

    Google Scholar 

  • Phillips AO. Renal failure and intravenous immunoglobulin. Clinical Nephrology 37: 217, 1992

    PubMed  CAS  Google Scholar 

  • Ramirez MV, Charlet M, Parry GJ. Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 42: 1636–1637, 1992

    Article  Google Scholar 

  • Rao SP, Teitlebaum J, Miller ST. Intravenous immune globulin and aseptic meningitis. American Journal of Diseases in Childhood 146: 539–540, 1992

    CAS  Google Scholar 

  • Rault R, Piraino B, Johnston JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clinical Nephrology 36: 83–86, 1991

    PubMed  CAS  Google Scholar 

  • Reinhart WH, Berchtold PE. Effect of high dose intravenous immunoglobulin therapy on blood rheology. Lancet 339: 662–664, 1992

    Article  PubMed  CAS  Google Scholar 

  • Rodeghiero F, Castaman G, Vespignani M, Dini E, Bertazzoni M. Erythema multiforme after intravenous immunoglobulin. Blut 56: 145, 1988

    Article  PubMed  CAS  Google Scholar 

  • Roifman CM, Lederman HM, Lavis S, Stein LD, Levison H, et al. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. American Journal of Medicine 79: 171–174, 1985

    Article  PubMed  CAS  Google Scholar 

  • Rossi F, Jayne DRW, Lockwood CM, Kazatchkine MD. Antiidiotypes against antineutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clinical and Experimental Immunology 83: 298–303, 1991

    Article  PubMed  CAS  Google Scholar 

  • Rostoker G, Phillipon C, Belghiti D, Ben Maadi A, Remy P, et al. Intravenous IgG for glomerulonephritis and renal function. Lancet 338: 54–55, 1991

    Article  PubMed  CAS  Google Scholar 

  • Schifferli J, Leski M, Favre H, Imbach P, Nydegger U, et al. High dose intravenous IgG treatment and renal function. Lancet 337: 457–458, 1991

    Article  PubMed  CAS  Google Scholar 

  • Schifferli J. Adverse effects of intravenous immunoglobulins. Transfusion Science 337: 331–338, 1991

    Google Scholar 

  • Siegel G, Byrne W, Cross A, Finbloom D. High dose intravenous immune globulin may impair host defences. Abstract. Clinical Research 333: 419A, 1985

    Google Scholar 

  • Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 42: 257–258, 1992

    Article  PubMed  CAS  Google Scholar 

  • Sultan Y, Kazatchkine MD, Maisoneuve P, Nydegger UE. Antiidiotypic suppression of autoantibodies to factor VIII (anti-haemophilic factor) by high dose intravenous gamma globulin. Lancet 2: 765–768, 1984

    Article  PubMed  CAS  Google Scholar 

  • Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from intravenous immunoglobulin therapy. Archives of Neurology 50: 137–139, 1993

    Article  PubMed  CAS  Google Scholar 

  • Van der Meche FGA, Schmitz PIM, Dutch Guillain-Barré Study Group. A randomised trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. New England Journal of Medicine 326: 1123–1129, 1992

    Article  PubMed  Google Scholar 

  • Williams PE, Yap PL, Gillon J, Crawford RJ, Urbaniak SJ, et al. Transmission of non-A non-B hepatitis by pH4 treated intravenous immunoglobulin. Vox Sanguinis 57: 15–18, 1989

    Article  PubMed  CAS  Google Scholar 

  • Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Correspondence. Lancet 2: 217–218, 1986

    Article  PubMed  CAS  Google Scholar 

  • World Health Organization. Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting. World Health Organization Bulletin 60, 43–47, 1982

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Level 7, John Radcliffe Hospital, Oxford, OX3 9DU, England

    Siraj A. Misbah &  Helen M. Chapel

Authors
  1. Siraj A. Misbah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helen M. Chapel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Misbah, S.A., Chapel, H.M. Adverse Effects of Intravenous Immunoglobulin. Drug-Safety 9, 254–262 (1993). https://doi.org/10.2165/00002018-199309040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199309040-00003

Keywords

Search

Navigation